Loading...
XNYSBIO.B
Market cap9.26bUSD
Dec 18, Last price  
325.85USD
Name

Bio Rad Laboratories Inc

Chart & Performance

D1W1MN
XNYS:BIO.B chart
P/E
P/S
3.41
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
-0.68%
Rev. gr., 5y
3.13%
Revenues
2.67b
-4.67%
1,090,012,0001,180,985,0001,273,930,0001,461,052,0001,764,365,0001,784,244,0001,927,118,0002,073,529,0002,069,235,0002,132,694,0002,175,044,0002,019,441,0002,068,172,0002,160,153,0002,290,109,0002,311,659,0002,545,626,0002,922,545,0002,802,249,0002,671,262,000
Net income
-637m
L-82.43%
68,242,00081,553,000103,263,00092,994,00089,510,000144,620,000185,490,000178,223,000169,234,00077,790,00088,845,000113,093,00028,125,000114,740,000360,996,0001,758,675,0003,814,229,0004,254,257,000-3,627,535,000-637,324,000
CFO
375m
+92.83%
123,093,000108,284,000118,229,000191,580,000191,371,000325,074,000225,909,000259,816,000278,898,000175,476,000273,312,000186,210,000216,433,000103,885,000285,494,000457,897,000575,328,000656,521,000194,447,000374,943,000
Earnings
Feb 13, 2025

Profile

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
IPO date
Mar 17, 1980
Employees
8,200
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,671,262
-4.67%
2,802,249
-4.12%
2,922,545
14.81%
Cost of revenue
1,466,843
1,491,808
1,553,541
Unusual Expense (Income)
NOPBT
1,204,419
1,310,441
1,369,004
NOPBT Margin
45.09%
46.76%
46.84%
Operating Taxes
(212,780)
(1,076,738)
1,192,247
Tax Rate
87.09%
NOPAT
1,417,199
2,387,179
176,757
Net income
(637,324)
-82.43%
(3,627,535)
-185.27%
4,254,257
11.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
(428,728)
69,370,220
35,232,002
BB yield
4.55%
-553.89%
-154.36%
Debt
Debt current
40,379
465
489
Long-term debt
1,560,787
1,387,649
233,887
Deferred revenue
9,648
1,770,481,000
(3,059,080)
Other long-term liabilities
204,713
(1,770,131,491)
3,417,209
Net debt
(7,702,546)
(9,239,010)
(15,028,108)
Cash flow
Cash from operating activities
374,943
194,447
656,521
CAPEX
(156,680)
(114,157)
(120,803)
Cash from investing activities
20,208
(1,207,593)
(784,438)
Cash from financing activities
(425,647)
973,576
(55,429)
FCF
1,172,000
2,043,025
254,772
Balance
Cash
1,607,142
1,796,232
875,478
Long term investments
7,696,570
8,830,892
14,387,006
Excess cash
9,170,149
10,487,012
15,116,357
Stockholders' equity
8,924,594
9,431,384
13,331,691
Invested Capital
1,416,561
1,699,130
658,276
ROIC
90.97%
202.53%
26.85%
ROCE
10.19%
10.16%
8.03%
EV
Common stock shares outstanding
29,209
29,785
30,208
Price
322.89
-23.21%
420.49
-44.35%
755.57
29.61%
Market cap
9,431,294
-24.70%
12,524,295
-45.13%
22,824,259
29.82%
EV
1,728,748
3,285,285
7,796,151
EBITDA
1,204,419
1,447,737
1,502,805
EV/EBITDA
1.44
2.27
5.19
Interest
49,439
38,114
1,551
Interest/NOPBT
4.10%
2.91%
0.11%